Vectus Biosystems
Research & Development into Cardiovascular Fibrosis & Blood Pressure. Vectus Biosystems holds patents around the Vasoactive Intestinal Peptide and its fragments as a therapeutic candidate to treat cardiovascular fibrosis and systolic blood pressure
- 11, Julius Ave, North Ryde, 2113, 2113, Sydney, New South Wales
- https://www.vectusbiosystems.com.au
Vectus Biosystems
Business Organisation